Related Experiment Videos
A refractory type asthmatic whose symptoms markedly improved by midaglizole.
T Nakazawa1, K Iizuka, Y Yoshie
1College of Medical Care and Technology, Gunma University, School of Medicine, Maebashi, Japan.
Summary
Midaglizole, an alpha-2 adrenoceptor antagonist, effectively treated refractory asthma. This asthma medication improved bronchodilation and lung function, reducing the need for other inhalers.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Asthma Research
Background:
- Intrinsic asthma presents a significant clinical challenge, often proving refractory to standard treatments.
- Alpha-2 adrenoceptors play a role in airway smooth muscle function, but their therapeutic targeting in asthma is less explored.
Observation:
- A patient with refractory intrinsic asthma was treated with midaglizole, a selective alpha-2 adrenoceptor antagonist.
- Immediate bronchodilation was noted after a single oral dose of midaglizole.
- Continuous administration over 4 weeks led to improved peak expiratory flow rate (PEFR) and reduced aerosol inhaler use.
Findings:
- Midaglizole demonstrated significant bronchodilatory effects in a patient with refractory asthma.
- A dose-dependent improvement in PEFR and a reduction in rescue medication use were observed with continuous midaglizole administration.
- The selective alpha-2 adrenoceptor antagonist showed efficacy as an add-on therapy.
Implications:
- Midaglizole may represent a novel therapeutic option for managing difficult-to-treat asthma.
- Targeting alpha-2 adrenoceptors could be a promising strategy in future asthma management.
- Further clinical trials are warranted to confirm these findings in a larger asthma patient cohort.